Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Sartore-Bianchi, A."'
Autor:
Patelli G; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy., Mauri G; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy., Tosi F; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Amatu A; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bencardino K; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bonazzina E; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Pizzutilo EG; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Villa F; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Calvanese G; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Agostara AG; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Stabile S; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Ghezzi S; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Crisafulli G; IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy., Di Nicolantonio F; Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Marsoni S; IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy., Bardelli A; Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia-IRCCS, Candiolo, Italy.; Department of Oncology, University of Torino, Candiolo, Italy., Siena S; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Sartore-Bianchi A; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Division of Clinical Research and Innovation, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Nov 14; Vol. 29 (22), pp. 4530-4539.
Autor:
Mauri G; IFOM-FIRC Institute of Molecular Oncology, Milan, Italy.; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy., Vitiello PP; Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo, TO, Italy.; Department of Oncology, University of Torino, 10060, Candiolo, TO, Italy., Sogari A; Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo, TO, Italy.; Department of Oncology, University of Torino, 10060, Candiolo, TO, Italy., Crisafulli G; Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo, TO, Italy.; Department of Oncology, University of Torino, 10060, Candiolo, TO, Italy., Sartore-Bianchi A; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, 20162, Milan, Italy., Marsoni S; IFOM-FIRC Institute of Molecular Oncology, Milan, Italy., Siena S; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, 20162, Milan, Italy., Bardelli A; Candiolo Cancer Institute, FPO-IRCCS, 10060, Candiolo, TO, Italy. alberto.bardelli@unito.it.; Department of Oncology, University of Torino, 10060, Candiolo, TO, Italy. alberto.bardelli@unito.it.
Publikováno v:
British journal of cancer [Br J Cancer] 2022 Aug; Vol. 127 (3), pp. 394-407. Date of Electronic Publication: 2022 Mar 09.
Autor:
Sartore-Bianchi A; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano (La Statale), Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Pietrantonio F; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lonardi S; Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy., Mussolin B; Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy., Rua F; Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy., Crisafulli G; Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.; Department of Oncology, University of Turin, Turin, Italy., Bartolini A; Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy., Fenocchio E; Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy., Amatu A; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Manca P; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bergamo F; Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy., Tosi F; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Mauri G; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano (La Statale), Milan, Italy.; IFOM, FIRC Institute of Molecular Oncology, Milan, Italy., Ambrosini M; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Daniel F; Medical Oncology Unit 1, Veneto Institute of Oncology IOV-IRCCS Padua, Padua, Italy., Torri V; Mario Negri Institute for Pharmacological Research-IRCCS, Milan, Italy., Vanzulli A; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano (La Statale), Milan, Italy.; Department of Services, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Regge D; Department of Surgical Sciences, University of Turin, Turin, Italy.; Unit of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy., Cappello G; Unit of Radiology, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy., Marchiò C; Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.; Department of Medical Sciences, University of Turin, Turin, Italy., Berrino E; Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.; Department of Medical Sciences, University of Turin, Turin, Italy., Sapino A; Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.; Department of Medical Sciences, University of Turin, Turin, Italy., Marsoni S; IFOM, FIRC Institute of Molecular Oncology, Milan, Italy., Siena S; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano (La Statale), Milan, Italy.; Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bardelli A; Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy. alberto.bardelli@unito.it.; Department of Oncology, University of Turin, Turin, Italy. alberto.bardelli@unito.it.
Publikováno v:
Nature medicine [Nat Med] 2022 Aug; Vol. 28 (8), pp. 1612-1618. Date of Electronic Publication: 2022 Aug 01.
Autor:
Manca P; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Corallo S; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Busico A; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Lonardi S; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology & Early Phase Clinical Trial Unit, Istituto Oncologico Veneto, IRCCS, Padua, Italy., Corti F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Antoniotti C; Unit of Medical Oncology, Azienda Ospedaliero-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy., Procaccio L; Unit of Medical Oncology 1, Department of Clinical and Experimental Oncology & Early Phase Clinical Trial Unit, Istituto Oncologico Veneto, IRCCS, Padua, Italy., Clavarezza M; Medical Oncology Unit, Ente Ospedaliero Ospedali Galliera, Genoa, Italy., Smiroldo V; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy., Tomasello G; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Murialdo R; Department of Internal Medicine (Di.M.I.), University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy., Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan & Department of Oncology and Hemato-Oncology, Università degli Studi di Milano (La Statale), Milan, Italy., Racca P; Medical Oncology Division 1, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., Pagani F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Randon G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Martinetti A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sottotetti E; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Palermo F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Perrone F; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tamborini E; Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Prisciandaro M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Raimondi A; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Bartolomeo M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Morano F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pietrantonio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. filippo.pietrantonio@istitutotumori.mi.it.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 May 01; Vol. 27 (9), pp. 2505-2514. Date of Electronic Publication: 2021 Feb 05.
Autor:
Patelli G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Piazza Ospedale Maggiore, 3, 20162, Milan, Italy., Vaghi C; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Piazza Ospedale Maggiore, 3, 20162, Milan, Italy., Tosi F; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Mauri G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Piazza Ospedale Maggiore, 3, 20162, Milan, Italy., Amatu A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Massihnia D; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Piazza Ospedale Maggiore, 3, 20162, Milan, Italy., Ghezzi S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bonazzina E; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Bencardino K; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Cerea G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Piazza Ospedale Maggiore, 3, 20162, Milan, Italy., Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. andrea.sartorebianchi@unimi.it.; Dipartimento di Oncologia ed Emato-Oncologia, Università degli Studi di Milano (La Statale), Piazza Ospedale Maggiore, 3, 20162, Milan, Italy. andrea.sartorebianchi@unimi.it.
Publikováno v:
Targeted oncology [Target Oncol] 2021 May; Vol. 16 (3), pp. 309-324. Date of Electronic Publication: 2021 Mar 18.
Autor:
Crisafulli G; University of Turin, Department of Oncology, Candiolo (TO), Italy.; Candiolo Cancer Institute, FPO - IRCCS, Candiolo TO, Italy., Mussolin B; Candiolo Cancer Institute, FPO - IRCCS, Candiolo TO, Italy., Cassingena A; Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Montone M; Candiolo Cancer Institute, FPO - IRCCS, Candiolo TO, Italy., Bartolini A; Candiolo Cancer Institute, FPO - IRCCS, Candiolo TO, Italy., Barault L; University of Turin, Department of Oncology, Candiolo (TO), Italy.; Candiolo Cancer Institute, FPO - IRCCS, Candiolo TO, Italy., Martinetti A; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Morano F; Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pietrantonio F; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Sartore-Bianchi A; Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Siena S; Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Di Nicolantonio F; University of Turin, Department of Oncology, Candiolo (TO), Italy.; Candiolo Cancer Institute, FPO - IRCCS, Candiolo TO, Italy., Marsoni S; IFOM - the FIRC Institute of Molecular Oncology, Milan, Italy., Bardelli A; University of Turin, Department of Oncology, Candiolo (TO), Italy.; Candiolo Cancer Institute, FPO - IRCCS, Candiolo TO, Italy., Siravegna G; University of Turin, Department of Oncology, Candiolo (TO), Italy giulia.siravegna@unito.it.; Candiolo Cancer Institute, FPO - IRCCS, Candiolo TO, Italy.
Publikováno v:
ESMO open [ESMO Open] 2019 Nov; Vol. 4 (6).
Autor:
Siravegna G; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.; Department of Oncology, University of Torino, Candiolo, Torino, Italy., Sartore-Bianchi A; Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Milan, Italy.; Department of Oncology and Haematology-Oncology, University of Milan, Milano, Milan, Italy., Nagy RJ; Guardant Health, Inc., Redwood City, California., Raghav K; The University of Texas MD Anderson Cancer Center, Houston, Texas., Odegaard JI; Guardant Health, Inc., Redwood City, California., Lanman RB; Guardant Health, Inc., Redwood City, California., Trusolino L; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.; Department of Oncology, University of Torino, Candiolo, Torino, Italy., Marsoni S; FIRC Institute of Molecular Oncology (IFOM), Milano, Milan, Italy., Siena S; Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Milan, Italy. alberto.bardelli@unito.it salvatore.siena@unimi.it.; Department of Oncology and Haematology-Oncology, University of Milan, Milano, Milan, Italy., Bardelli A; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy. alberto.bardelli@unito.it salvatore.siena@unimi.it.; Department of Oncology, University of Torino, Candiolo, Torino, Italy.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 May 15; Vol. 25 (10), pp. 3046-3053. Date of Electronic Publication: 2019 Feb 26.
Autor:
Germano G; Candiolo Cancer Institute-FPO, IRCCS, Candiolo (TO), Italy., Mauri G; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Siravegna G; Candiolo Cancer Institute-FPO, IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Torino, Candiolo (TO), Italy., Dive C; Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK., Pierce J; Cancer Research UK Manchester Institute, University of Manchester, Manchester, UK., Di Nicolantonio F; Candiolo Cancer Institute-FPO, IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Torino, Candiolo (TO), Italy., D'Incalci M; Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy., Bardelli A; Candiolo Cancer Institute-FPO, IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Torino, Candiolo (TO), Italy., Siena S; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy; Dipartimento di Oncologia e Emato-Oncologia, Università degli Studi di Milano, Milan, Italy., Sartore-Bianchi A; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy. Electronic address: andrea.sartorebianchi@ospedaleniguarda.it.
Publikováno v:
Clinical colorectal cancer [Clin Colorectal Cancer] 2018 Mar; Vol. 17 (1), pp. 80-83. Date of Electronic Publication: 2017 Nov 01.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, Benedetta Mussolin, Francesco Rua, Giovanni Crisafulli, Alice Bartolini, Elisabetta Fenocchio, Alessio Amatu, Paolo Manca, Francesca Bergamo, Federica Tosi, Gianluca Mauri, Margherita Ambrosini, Francesca Daniel, Valter Torri, Angelo Vanzulli, Daniele Regge, Giovanni Cappello, Caterina Marchiò, Enrico Berrino, Anna Sapino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli
Publikováno v:
Nature Medicine
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that